Programmed cell death protein-1 (PD-1), as an
immune checkpoint molecule, attenuates T-cell activity and induces T-cell exhaustion. Although
siRNA has a great potential in
cancer immunotherapy, its delivery to target cells is the main limitation of using
siRNA. This study aimed to prepare a liposomal formulation as a
siRNA carrier to silence PD-1 expression in T cells and investigate it's in vivo antitumor efficacy. The liposomal
siRNA was prepared and characterized by size, zeta potential, and biodistribution. Following that, the uptake assay and
mRNA silencing were evaluated in vitro at
mRNA and
protein levels. siRNA-PD-1 (siPD-1)-loaded
liposome nanoparticles were injected into B16F0
tumor-bearing mice to evaluate
tumor growth, tumor-infiltrating lymphocytes, and survival rate. Liposomal siPD-1 efficiently silenced PD-1
mRNA expression in T cells (P < 0.0001), and siPD-1-loaded liposomal nanoparticles enhanced the infiltration of T-helper 1 (Th 1) and cytotoxic T lymphocytes into the
tumor tissue (P < 0.0001). Liposome-PD-1
siRNA monotherapy and PD-1
siRNA-
Doxil (
liposomal doxorubicin) combination
therapy improved the survival significantly, compared to the control treatment (P < 0.001). Overall, these findings suggest that
immunotherapy with siPD-1-loaded
liposomes by enhancing T-cell-mediated antitumor immune responses could be considered as a promising strategy for the treatment of
melanoma cancer.